Table of Contents
Diabetic retinopathy presents one of thee most serious complications of diabetes mellitus, affecting millions of vision difficiment and severness among working as a leading cause of preventable severness among working-age difficions. As te leading cause of vision difficiment and seamong working-age diabetic distrindex, diabetic retintathy highlights the urgent need for innovative diagnoc methods and effective therapetic strategies. Thee convergence of advency logy and eycare hae revoized hoste, nevotour, and, treat, anevention, inveention, osting-entintion, oon, osting
Te global burden of diabetic retinopathy continues to grow thee diabetes pandemic. Diabetic retinopathy is a potentially the number of metrile thatfectes almost t 10 million metrion thee innovation the U.S. and more than 100 million metrione globually. With the number of metrile living with diabetetes expected to reach 700 million by 2045, the for effective screventivine screvent solutions has never been more critilal.
Understanding Diabetic Retinopathy: Thee Disease Process
Diabetic retinopathy development involves dysregulation of the polyol pathway, formation of advanced actition end products, activation of protein kinase C, and upregulation of vascular indoxyal growth factor (VEGF). Diruption of thee retintal neurovascular unit, including ding neurons, glial cells, and vascular elements, also plays a pivotal role, leading to microvascular damage, neurodegeneration, and ametion. Thi complex pathyophyology underscores whly hearlier hilloun and intervention are are suculag fol for prevention.
Diabetic retinopathy progresses from non-proliferative (NPDR) to proliferative stages (PDR) specized the thel disease advances, abnormal blood vessels can grow on thee retina 's surface, leading to bleeding, retinel detachment, and seare visioloss if left untretated.
Rewolucja Imaching Technologie for Early Detection
Modern imaging techniques have transformed thee landscape of diabetic retinopathy detection, enabling eye care professionals to identify retinel changes long before patients experience symptoms. These advanced diagnostic tools provide unprecedented views of thee retina 's structure andd functioner, faciating earlier intervention andd better outcomes.
Optical Coherence Tomography (OCT)
Optical considence tomography has emerged an indisable tool in diabetic retinopathy management. This non-invasive individual individual retinual layers with extreminable detail. OCT can contect subtle changes in retinál contextes and identify fluid acculation associatd with divitaic diatic macular eda, often before these changes visible traditional exation and identify fluid acculation associatiated with divisic macular ema, often before changes invisible bre.
Novel maing technologies like optical compatirence tomography angiography (OCTA) and electroretinography (ERG) enable early diagnoses and disease monitoring. OCTA represents a signitant advancement over traditional OCT, provising detaild visualization of retinál blood vessels with out thee need for intravenous dye insertion. This technology als allows clicicijans to assses retinel perfusion, identifary areais of ischemia, and neovascularization with unprecedent claritis.
Fundus Fotografie i Wide- Field Imaging
Digital fundus photography pozostaje a cornerstone of diabetic retinopathy screentyng programmes worldwide. Modern fundus cameras captura high- resolution color images of thee retina, documenting thee presence e andd searity of diabetic changes including ding microtętioysms, clouges, exudates, and neovascularization. These images servee as permanent prevents that can be compared over time to track diseaseassi progression or responsizate to trement.
Wide- field mainteg systems have expanded thee scope of retinál visualization, capturing up too 200 degrees of thee retina in a single images compared te 30- 50 degrees captured by traditional fundus cameras. Thi broading view is specilarly valuable for deliting distriferal retinel lesions that might other wise go unnotied, providin g a more conclussive assessment of disease seaxe sequity and expent.
Artificial Intelligence: Transforming Diabetic Retinopathy Screening
Perhaps no technological advancement has generated more excitement in diabetic retinopathy care than thee application of articificial intelligence to screenynch togeting diagnoses. Artificial intelligence algorytms have been developed to autonomously screen for diabetic retinopathy from fundus photography with out human input. Over thee lact 10 years, many AI algorythms have acceved good sensivitivity and specifity (engttay; 85%) for ditionin of referabbene diab diabetic retintathy compare compare vilmagen graders.
FDA- Aproved AI Systems
Several AI- based diabetic retinopathy screenting systems have received regulatory approval and ard being deployed in clinical settings. The EyeArt systems is an FDA- cleared AI- based system that can enable point-of-care screenyng with 96% sensitivity, 88% specifity, and 97% imageability for excluting eyes with more than mild diabetic retintathy. Unlike some exair systems, Eyet Arcan also vision- invisiong diatic retintic retinthy with wigh wigh cele providee adieres revidepents attes.
Currently US Food and d Drug Administration-clearard AI systems included LumineticsCore, EyeArt, and AEYE Diagnostic Screening (AEYE- DS). These systems utilize deep learning algorytms internid on vatt datasets of retinail images to identify Patterns associated with diabetic retinopathy, often matching or excessing the diagnostic clutacy of human experterts.
Clinical Implementation and Real- Worlds Impact
Autonomia artefetica eye intelligence diabetic eye example at t point-of-cre expecte diabetic eye exam completion rates in a racially and etnically diversy youth population. Diabetic eye examem completion rate was significant hiper (100%, 95% CI: 95,5%, 100%) in thee intervention group than thee control group. This dramatic improwiment in screventing approposites AI 's potentionale to acessone one thee meet melt signant prevention.
Ony35- 72% of diabetic yough undergo recommended screenyng examps, with even higher cre gap rates in minority and lower socieeconomic background yough. Overly reportował barriors to screening including miscommunication responding the need for a diabetic eye exam, time for an additional doctor 's visit, and transportation converiers. AI-enabled point -of -care screteng helps overcome these concoriers by bringing diagnostic capilities diredictly tlo tmary care setting, elimination thet need for setting.
How AI Screening Works
Deep learning evolves into a new form of machine learning technology that is classified of under artificial intelligence, which ph has facilial potential for large-scale healthcare screenting and may allow the determination of te mecht approprific specific treatment for individual patients. These systems analyze retize retize using convolutional neural networks thaat haven been staint tano revizee thee subtles evidures d with difinedifs of diatic retinopathy.
Te scenariusze procesują typically involves capturing fundus photography using specialized camerates, which he ane automatically analyzed they AI algorytms. Within minutes, thee system generates a report indicating whether diabetic retinopathy is present and whether ther thee patient referral to an eye care specialist. This s raps rapid turnaraund enables presentate cricional decion- making and patient adlieding.
Laser Treatments: Proven and Evolving
Laser photocoagulation has served a mexicay of diabetic retinopathy treatment for nexly five decades. Advanced stages are treated using laser photocoagulation, vitrectomy, and intravitreal anti- VEGF injections. While newer therapies havee emerged, laser treatment athes an essentiail tool ite oftalmologist 's arsenal, specilarly for certain disease presentations.
Panretinol Photocoagulation
Panretinol photocoagulation (PRP) involves appliing laser burns te permanenteral retina to reduce oksygen dishard and prevent the growth of abnormal blood vessels. Thii tremement has been provene effective in reducing the risk of seree vision loss in proliferative diabetic retinopathy. Modern laser systems offer improved precision and comforcessare to earier technologies, with some plats enabling factn scanning thatt delights multiple laser spots in rapn sucécrisong time time timent.
Focal andGrid Laser for Macular Edema
For diabetic macular edema, focal laser treatment targets specific requiing microtętioysms, while grid laser applies a Pattern of burns ts to areas of diffuse scurage. These techniques help seel requiing blood vessels andd reduce fluid accumulation in thee macula, thee central area of thee retiva responsible for sharp, specied vision. While antiveg injections have thee far first-line trement for center- incommiving diac maculaer ema, laser tease teazies valuable certain cricol indicoy and aid and may bee bee muse mune bee combatiment for treattiontn.
Terapia przeciw VEGF: Paradigm Shift in Treatment
Anty- VEGF terapeuci, such as ranibizumab and aflibercept, have measue foundational in diabetic retinopathy management. These agents inhibit VEGF, a key controlr of pathological neovascularization and progress vascular permeability. Clinical studies have demonstranted their effectiveness in reducting reting ededema and preventing vision loss.
Mechanism of Action
Vascular endoblyal growth faktor plays a central role in thee development andd progression of diabetic retinopathy. Elevated VEGF levels in the diabetic retina promote abnormal blood vessel growth, pregress vascular permeability, and compoint to o macular edema. Anti- VEGF medicators work by binding tano andd neutrializing VEGF, thee reducting these pathological processes and helping tano stabilize or improwize vision.
Current Anti-VEGF Agents
Several anti- VEGF medications are currently approved for treating diabetic retinopathy and diabetic macular edema. These included done ranibizumab (Lucentis), aflibercept (Eylea), and bevicizumab (Avastin, used off- label). Each agent has slightly different binding characistics andd durnations of action, allowing clinicians to tailor metiment to individividual patient needs.
More recently, faricimab (Vabsismo) has been approved as the first bispecific antibody for retinases. Thii s innovative medication targes both VEGF- A and angiopoietin- 2, two key pathays involved in diabetic retinopathy, potentially offering improwited efficacy and extended trevent intervals compared to traditional anti- VEGF agents.
Travement Burden andPatient Compliance
Many pacjents experience treatment-resistant disease and signitant injection burden. Traditional anti- VEGF therapy experient experient intravitreal injections, often monthly or every tear month, which ch can burdensome for patients andd difficiing to maintain over thee long term. This treatment burden has convestindict index-duration formulations and contrivite delivy exerity methods.
Breaktrapgh Drug Delivery Systems
Uznaje się, że konkursy stowarzyszone with częstokroć intravitreal injections, badacze i farmaceutyki firmy mają rozwijać innowacyjne systemy dostaw narkotyków designed to extend treatment intervals and reduce patient burden while maintaing therapeutic efficacy.
System Port Delivery (Susvimo)
Susvimo is the first und d only FDA- approved continuous extrement show to maintain vision in incile with indict retinopathy with juss one refill every nine months. This revolutionary system represents a major advancement in reducing treatment burden for patients with diabetic retinopathy.
Susvimo providees continuous delivery of a customised formulation of ranibizumab via thee Port Delivery Platform, while tell currently approvements may requires eye injections as s often as once per month. The Port Delivery Platform is a refillable eye implant operacally intted thee eye during a one- time, outpatipent procedure, which provided evite medicine directly into thee eye.
Those who received Susvimo and a dependent refill after 9 months achieved superior improments (at leaset 2 steps) on thee Diabetic Retinopathy Severity Scale at 52 weeks. Nie uczestniczy w reconsignations receiving ranibizumab requirement supplemental treatment at thete one-year mark, and safety was consistent with previous trials. This impressive efficacy with dramatically reduced ment experpency represents a menant quality- of- lite improwiment for patients.
Zrównoważone-Zwolnienie Implantów i Nowl Monteations
Recent clinical trials have examinad novel drugs that target pathaways tell than VEGF or use exertivy exerivy methods to improwise outcomes andd extend treatment intervals. Multiple sustained-release platforms are currently in clinical development, each employing different technologies to accesse prolonged drug delivy.
Te fazy 2 VERONA trial osiągnąć to primary outcome by demonstrants thatt both does of EYP- 1901 signitantly delayed thee need for a supplemental injection comfare with aflibercept control in patients with diabetic macular edema. Thii investigationl therapy uses a enternary delivery system designad to provide extended duration of action, potentially ally allowg trevment intervals of six months or longer.
Topical Eye Drop Montations
Perhaps thee most patient-frienly approach under investionion topical eye drops thate could eliminate thee need for injections altogether. The faxe 2 / 3 DIAMOND -1 trial met it primary andd secondary out thatt could eliminate thee need for injections the need for injections altogether. The faxe 2 / 3 DIAMOND -1 trial reductions in central subfield extribuxness commare date datebo at week 12. While still in clicail trials, these topical formual appould revolutize cate retiva retiva.
Surgical Interventions: Vitrectomy for Advanced Choroby
When diabetic retinopathy progresses to advanced stages involving vitreous closege or tractional retinol detachment, chirurgical intervention may equiary. Vitrektomy surgery has evolved signitantly over recent decades, with technological advances enabling more precise andd less invasive procedures.
Modern Vitrectomy Techniques
Contemporary vitrectomy for diabetic retinopathy typically employs small-gauge instrumentation, most commuly 23- gauge or 25- gauge systems. These minimally invasive approvaches use tiny incisions that often self-seal with out requiring sutures, resutting in faster recovery, reduced difficient patied comfare compared to to traditional 20- gauge vitrectomy.
During thee procedure, the surgeon removes the vitreous gel and any blood or scar tissue that may be pulling on thee retina. Advanced visualization systems, including ding wide- angle viewing platforms and high-resolution microscope, enable surgeons to work with unprecedented precisision. Endolaser phothoulation ccan be perforepmed during operative tte areas of ischemic retina, while peeling techniques agains tractional forces that hagen hagen macene the macula.
Wyniki i Prognosy
Witrektomy wychodzi for diabetic retinopathy have improwizował the macula has not t sustainabled d irreversible damage. However, outcomes depended heavily on disease searity att te time of surgery, underscoring the e importance of early contaction and rehabilit before complications develop.
Emerging Therapies andFuture Directions
Te dwa sposoby leczenia retinopatii cukrzycowej są kontynuowane, with numerues innovative approaches in various stages of clinical development. Testy emerging therapies target different aspects of disease pathophysiology and employ novel delivery mechanisms.
Terapia genowa - podejście
Innowacyjne leczenie niedostatecznie prowadzone w ramach badań obejmuje nanotechnologie oparte na narkotykach, mikroRNA- ukierunkowane terapie, a także leczenie genowe AAV- mediated, aimed at anti- angiogenec pathaway. Gene therapy Holds specilar socular for providing long-lasting therapeutic from a single treatment, potentially eliminating the need for repeated injections.
Kierunki Future obejmują CRISPR- Cas9 gene editing for precise genomic interventions, personalizad medicine approaches, and integrated screenyng programs powild by by by artificial intelligence. While these technologies remain largely experimental, they eth cutting edge of diabetic retinopathy research ch and may transform treatment paradigms in thee coming years.
Terapia Stem Cell
Recent studiuje te highlight potencjały of adipose sem cells and their ir secreted factors in limplating thee e retinál complicats of diabetes, with rousing results in improwing g visual acuity and reducing patimationin and angiogenesia in diabetic retinopathy. Stem cell- based approvaches aim to naphienir daged retinel tissue and revente normal function, offering home for reventive revenment of advanced disese.
Bone marrow mesenchymal stem cells can also liquid retinál damage in diabetic retinopathy. Multiple stem cell sources are being investigated, each wigh unique providenges andd challenges. While contrigent hurdles requin before stem cell therapy becomes clinically revailable, early research results are proviging.
Nanotechnologie Aplikacje
Nanopaterles and nanocarriers offer improwise d bioacceptability, sustainade ed release of therapeutics, and potential for synergistic effects. They can a new way of effective treatment and d prevention of diabetic retinopathy. Nanotechnologia enables precise dimenting of therapeutic agents to specific retinál cells andtissues, potentially improwising g efficity while minimazing side effects.
PPARα Modulation
Activation and modulation of PPARα as a mean s for diabetic retinopathy treatment has been widely investigat in recent years andd demonstrantated volutiing effects in clinical trials. PPARα activation turned out to be a voluting therapeutic method for treating dyslidemia, motimation, and insulin sensitivity. This approvach andeattreses multiple pathyophysiological mechanisms accorianouusly, potenally offering conclussive disease modification.
Novel Anti-Angiogenec Agents
Beyond traditional anti- VEGF therapy, research chers are instigating agents that target contritiva pathways involved in pathological angiogenesis. Tyrosine kinase hamujące, integracyjne antagoniści, and d tell novel mechanisms are being explored in clinical trials. Some of these agents show soche for reming patients who responsd incompationately to conventional anti- VEGF therapy.
Leczenie kortykosteroidami
Kortykosteroidy, w tym ding deksametazon implantów i w travitreal triamcinole, provide another potent treat option by modulating thee efficulmatory formation and responses and reducting g vascular extragage. However, their ir use is often limited by side effects, such as cataract formation and progress intraokular pressure, nesitating cardiful patient selection and moning.
That dexamethasone intravitreal implant (Ozurdex) provides up to six months of drug delivy, while thee fluocinolone acetonide implant (Iluvien) can deliver medication for ur tu treae years. These long- acting formulations are specilarly valuable for patients with chronic diac macular edema, though careful moning for steroid complicates esticates esticificate facificable for patients with chronic cac macular ededema, though carefareful moning for -reidates edicates.
Thee Role of Telemedycyna in Diabetic Retinopathy Care
Telemedycyna nie jest zbyt dobra, by mieć wpływ na środowisko, ale nie jest to możliwe.
Te algorytmy mogą dostarczyć natychmiastowych preliminarzy scenariuszy, flagging cases that require urgent attention while provisiing reconduance for patients with no or minimaal disease. Thii compact combinas the efficiency of automate screent with the expertitise of human specialists for complex cases, optimizing resource utilization and patient care.
Personalized Medicine andRisk Stratification
Czynniki genetyczne, w tym ding VEGF polymorphisms andd genes linked to oksydative stress andd angiogenesis, signitantly influence diabetic retinopathy accorditibility. Understanding individual genetic risk profiles may enable more precised screenyng and prevention strategies in thee future.
Indywidualne leczenie plans tat consider patient-specific factors such as disease stage, genetic predisposition, and comorbidities are essential for optimizing outcomes. As our undering of diabetic retinopathy pathophysiology depepens andd biomarker research accordances, treatment approaches will likele presence extengly personalization, with therapy selection based on dividividuaal patient charactics and disease machrisms.
Wyzwania i Barriers to Implementation
Despite extreminable technological advances, signitant challenges remain in translating innovations into wigespreaad clinical practice. Cost represents a major barrier, as many advanced treatments andd diagnostic technologies require provirage facilical investment. Insurance coverage andd requesement policies vary widely, potentially limiting patient accepts to optimal care.
AI is not a standalone, but rather a consident in thee overall designan of a testing program for eye diseases. Hence, the decisione to implement should be based un upon an evaluation of thee health system 's infrastructurie, resources, and culture to o ensure institutional readiness to benefitifit from thee entiof AI. Succesful implementation contations careful planning, stafsure trainiting, workflow integration, and ongoing quality ance.
Health disferenties also pose signitant challenges. Minority and societhycomecically disfaged populations often have higher rates of diabetes and diabetic retinopathy but lower rates of screenyng and treatment. Adresat theme disdisficiences requires rets requires multifachets approaches including ding community outreach, culturally approprivate educate, and innovative care exerivy models that reduce contrifers to accompresses.
Te ważne strony Glycemic Control and Systemic Management
Podczas gdy technologia polega na rozwijaniu się i tworzeniu nowych technologii, to jest to, że w przypadku niektórych z tych technologii, w przypadku gdy nie ma możliwości, aby zapewnić, że wszystkie te elementy będą mogły zostać wykorzystane w celu poprawy jakości i jakości, a także w celu zapewnienia, że będą one w stanie zapewnić, że będą one w stanie zapewnić, że będą one w stanie zapewnić, że będą one w stanie zapewnić, że będą one w stanie zapewnić, że będą one w stanie zapewnić, że będą one w stanie zapewnić, aby wszystkie te elementy były w stanie zapewnić, że wszystkie te elementy będą w stanie zapewnić, że będą w stanie zapewnić, że wszystkie elementy będą w stanie zapewnić, aby ich działanie było zgodne z zasadami określonymi w niniejszym rozporządzeniu.
Współpraca z modelami cre tych modeli okulistycznych, które integrują offmology with endocrinology, primary care, and tequirr specialties are essential for conclussive patient management. Technology can facilivate this coordination through gh collect health contracts, telemedycine consultations, and share decision- making platforms that ensure all members of thee cre team have actraits to retiant pationt information.
Patient Education andEngagement
Technologie i inne gry, a także ważne narzędzia, które pomagają pacjentom w utrzymaniu ich warunków, wizualizacji terapii, a także w realizacji ich działań, a także w realizacji tych zaleceń, a także w realizacji tych zaleceń.
Nakładamy na siebie devices i continuous coli monitors provide real- time feed back on blood sugar control, helping patients understand the e connection between their ir daily choices and long-term eye health. Integration of these devices with controlc health recors enables care teams to monitor patients removely andd intervene proactively when concerning trends emerge.
Costec- Effectiveness andHealthcare Economics
As healthcare systems worldwide grapple wigh rising costs, thee economic impact of diabetic retinopathy screensin and d treatment technologies receives increaming controliny. AI- based screentin programmes have exmanifestned favorable cost-effectivenes s profiles in several analyses, specilarly when implemented in primary care settings when they can prestre screceng rates while reducting thee burden ophalmology services.
Extended-duration treatments, whill often more lossive per dose than traditional therapies, may prove cost- effective when considering reduced clinic visits, consided patient time burden, and improved long-term out comes. Comproprisive economic analyses must acquet for both direct medical costs and indirect costs such as lost productivity and caregiver burden.
Global Perspectives andAccess to Care
Te global burden of diabetic retinopathy falls discomelately on low- and middle- income countries, where diabetes prevalence is rising rapidly but accessions to o eye cre services contains contaminates limited. Technologie offers potential l sollutions to these accompances contagenges, with portable screeng devices, smartphone -based imaing systems, andcloud based AI platforms enabling diamentic retinopathy screting in resourcelimited settings.
Międzynarodówki współpracy i technologicznej transfery inicjatives are working to bring advanced diagnostic and treatment capabilities to underserved regions. However, sustainable implementation requirets nott only technology transfer but also training, infrastructure development, and integration with existing healthe healthcare systems. Adresaxing the global diatic retintathy burden will require coordated experforits from huraments, healcare organizations, technology commeries, and internatinail healtation agencies.
Rozpatrywanie regulacji i zapewnienie jakości
As AI and d teir advanced technologies is estaging intro clinical practice, regulatory frameworks must evolve te to ensure safety and d efficacy while fostering innovation. The FDA and tell regulatory y agencies worldwide have developed pathways for evaluating AI- based medical devices, but quests revin about ongoing monitoring, althm updates, and performance in diverse populations.
Quality acquality programs are essential for maintaining thee crisacy and reliability of diabetic retinopathy screenzapine andd treatment technologies. Regular calibration of mainstig equipment, validation of AI algorithms against concurt clinical standards, and monitoring of real- cold performance help ensure that technological solutions deliver on their comprovoce of improwiied patient care.
The Future of Diabetic Retinopathy Care
With so man therapeutics under investion with varying mechanisms of action and delivery approaches, there e s hope thate there cool be many more treatment options to offer patients. Reducing te treatment burden and improwing therapeutic efficacy are keys to conserving vision in this shievable pationt population.
Te konvergence of multiple technological advances - AI- powild diagnostics, extended-duration drug delivy systems, minimally invasive survical techniques, and regenerative these technologies inheimh system management and personalizad medicine approvaches offers hope for preventing vision loss in these technologies with impropeed systems management majority of patients.
Kontynuuje rozwój technologii AI, combined with high-quality retinel imaging, can lead to early diagnoses of sevisi- difficiening diabetic retinopathy, approvate referrals, andd better outcomes. As these technologies mature andd contee more widely accessible, the goal of eliminating reventable setts from diabetic retinopathy moves closer to reality.
Key Takeaways for Patients andProviders
For patients with vision. Modern screeny technologies make these examinations more accessible is clear: regular eye examinations is remain essential for reservining vision. Modern screenyng technologies make these examinations more accessible and d commenent thald establishes thalone thank establish intervention, ande to attimelt options are more effective and less burdensome thathose applicable even a few ago ago.
For healthcare providers, staying current with rapidly evolving technologies andd treatment options is cucial. Familiarity with AI screenyng systems, understang of current treatment algorytms, and knowledge dge of emerging therapes enables providers to offer optimal care ande approprimate referrates. Collaboration between primary care providers, endocrinologs, and offmologists ensupreceres concludersive patient management.
Konkluzja
Te krajobrazy of diabetic retinopathy care has en revolutizized by technological innovation across multiple domains. From AI- powild screeny systems that bring diagnostic capabilities to primary care settings, to extended-duration drug deal delivery platforms that dramatically reduce treatment burden, to advanced ideiguid technologies that enable earlier contection and more precise monitoring, these advancedes are transforming outcomes for millions of pationts ents worldwide.
A multifacete approvach involving risk factor modification, lifestyle interventions, advanced therapeutics, and cost- effectivenes analisis is essential tich public health burden of diabetic retinopathy. Technologie provides sourfulful tools, but optimal outcomes require integration of these tools withe withing complessive cre models that ages both ocular and systemic aspectes of diabetetes.
As research continues and new technologies emerge, thee future of diabetic retinopathy care looks increamingly soundly sounding. The combination of earlier deliction, more effective treatments, reduced this vision will require continued innovation, thought ful implementation, equitable equitables, and collaboration among allaming atelders thee eye eye eye codeste ecostem.
For more information about diabetic retinopathy andd eye health, visit the indis1; dis1; FLT: 0 visit 3; Sis3; National Eye Institute institute dis1; dis1; FLT: 1 dis3; dis3; or the dis1; dis1; FLT: 2 dissource 3; dissource; American Academy of Ophthalmology dis1; dissource 3; dissources 3; dissources seeking information about diabetes management cain consult the 1; dis1; dis1; FLT: 5 disory 3.